Search results for: revocation

GJE Partner, Arnie Clarke, Leads Successful Landmark Opposition Attack of Teva’s Key 2030 Patent (EP 2 949 335) On Behalf of Mylan

Arnie Clarke has recently been involved in the ground-breaking appeal relating to Teva’s key 2030 patent (EP 2 949 335).  Acting on behalf of Mylan, in front of the EPO board of appeal 3.3.04, ...

Being Heard and Seen – Oral Proceedings During the Time of Coronavirus

A recent decision of the Boards of Appeal of the European Patent Office makes it clear that oral proceedings can take place via videoconference.  This paves the way for the backlog of hearings that h...

Santen: A Clear View of Drug Repurposing and a Loss of Sleep for Those Relying on Neurim

The CJEU has dealt a massive blow to the drug repurposing sector with its decision in Santen, stripping companies of their right to Supplementary Protection Certificates (SPCs), and overturning one of...

The Medtech Patent Landscape in Numbers – 2020 Update

A few years ago we analysed the MedTech sector from a patents perspective (see here).  Many of the wider trends that we identified have continued, while there has been some shifting in the specif...

Marking Time: Do Patent Numbers Have Any Place on Watches and Other Luxury Goods?

We often advise clients that any product made in accordance with their granted patent should be suitably marked as patented.  While there is no requirement for this in UK law, patent marking of p...

Chemical Oppositions – Can Experimental Data be the Key to Success? Part 1

There is a nine-month window in which anyone can oppose the grant of a European patent.  If the opponent is successful, the patent can be limited to a scope that they can work around, or the patent c...

The Chemistry of Collaboration

From Paul Allen founding Microsoft with Bill Gates, to Ben and Jerry creating their much loved ice cream flavours, many of our modern technologies and luxuries are the product of collaboration. Those ...